19 studies found for:    15175435 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Angiogenesis Inhibitors and Hypertension: Clinical Aspects
Condition: Hypertension
Intervention:
2 Unknown  Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema
Condition: Lymphedema
Intervention: Drug: Bevacizumab
3 Withdrawn A Study of Bevacizumab to Prevent Malignant Ascites
Condition: Malignant Ascites
Intervention: Drug: Bevacizumab
4 Completed
Has Results
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study
Condition: Metastatic Malignant Melanoma
Interventions: Drug: Avastin;   Drug: Abraxane
5 Terminated Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
Conditions: Colorectal Cancer;   Metastases
Interventions: Drug: Cetuximab;   Drug: Bevacizumab;   Drug: Leucovorin;   Drug: Oxaliplatin;   Drug: Fluorouracil
6 Recruiting Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Capecitabine;   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Irinotecan
7 Terminated
Has Results
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Condition: Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Docetaxel;   Drug: CPT-11;   Drug: Paclitaxel;   Drug: Vinorelbine Tartrate;   Drug: Gemcitabine
8 Active, not recruiting Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
Conditions: Esophageal Neoplasms;   Stomach Neoplasms;   Neoplasm Metastasis
Intervention: Drug: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
9 Active, not recruiting Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab
Conditions: Colorectal Cancer;   Metastasis
Intervention: Biological: Bevacizumab + blood samples
10 Recruiting Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: aflibercept + FOLFIRI
11 Terminated A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
Conditions: Colorectal Cancer;   Steatohepatitis
Intervention: Drug: Metformin/Placebo
12 Recruiting Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
Conditions: Gastrointestinal Neoplasms;   Cancer of Gastrointestinal Tract;   Cancer of the Gastrointestinal Tract;   Gastrointestinal Cancer;   Neoplasms, Gastrointestinal
Intervention:
13 Completed
Has Results
Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
Condition: Recurrent Respiratory Papillomatosis
Interventions: Drug: Avastin® (bevacizumab);   Drug: Saline
14 Completed Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy
Condition: Rectal Cancer
Intervention: Drug: preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
15 Recruiting Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.
Condition: Metastatic Colorectal Cancer
Interventions: Procedure: Metastases resection;   Drug: Bevacizumab;   Drug: 5 FU (5Fluorouracile);   Drug: Oxaliplatine;   Drug: Irinotecan
16 Recruiting Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
Condition: Metastatic Colorectal Cancer
Interventions: Procedure: Metastases Resection;   Drug: 5-Fluorouracile;   Drug: leucovorin L;   Drug: Oxaliplatin;   Drug: Irinotecan;   Drug: Cetuximab
17 Completed Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.
Condition: Breast Cancer
Interventions: Behavioral: Exercise Training;   Behavioral: Chemo only
18 Completed Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Conditions: Ovarian Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Drug: Pemetrexed;   Drug: Bevacizumab
19 Unknown  Evaluation of Contrast-Enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases
Condition: Metastatic Colorectal Cancer
Intervention: Device: real-time contrast-enhanced ultrasound imaging (CEUS)

Indicates status has not been verified in more than two years